EIF4A1 and pancreatic neoplasm: The eIF4A1 inhibitor Rocaglamide (RocA) and the c-Myc inhibitor Mycro3, alone or in combination, significantly reduced the expression levels of markers of epithelial mesenchymal transition in pancreatic cancer cells (ZHAO et al., 2021).